ViewPoint was developed in 2014, and focuses on non-surgical treatments to correct protein misfolding in lenses, which can lead to presbyopia and cataracts.
Visus, which is currently conducting two phase 3 trials to study eyedrops to treat presbyopia, will use ViewPoint’s assets to advance development of other treatments for age-related vision loss, according to a news release from the company.
“The ViewPoint acquisition provides an extensive library of potent drug candidates with highly desirable pharmaceutical properties for ocular delivery,” Rhett Schiffman, MD, Visus’ co-founder and chief medical officer, said in a Sept. 28 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.